Mutation analysis of Phenylalanine hydroxylase gene in Iranian patients with Phenylketonuria by Moghadam, M.R. et al.
Original Article 
http://mjiri.iums.ac.ir  
Medical Journal of the Islamic Republic of Iran (MJIRI) 
Med J Islam Repub Iran. 2018(11 Mar);32.21. https://doi.org/10.14196/mjiri.32.21
______________________________ 
Corresponding author: Dr Farideh Ghazi, ghazi.f@iums.ac.ir 
1. Department of Medical Genetics and Molecular Biology, School of Medicine, Iran
University of Medical Sciences, Tehran, Iran. 
2. Department of Pediatrics Endocrinology and Metabolism, Ali Asghar Children’s
Hospital, Iran University of Medical Sciences, Tehran, Iran. 
↑What is “already known” in this topic: 
Phenylketonuria is one of the most prevalent metabolic genetic 
disorders. Mutations in phenylalanine hydroxylase gene cause 
this disease. More than 800 different mutations are registered 
on the PAH mutation database.   
→What this article adds: 
Mutation analysis of PAH gene study (exons 6, 7, 8, 11 and 12) 
in Iranian patients with PKU was screened. These mutations 
showed regional variations useful in genetic counselling and 
prenatal testing in different ethnic groups. We found three nov-
el intronic variants and two previously unreported mutations. 
Our data proved the heterogenic status of PAH gene mutations.  
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Abstract 
    Background: Phenylketonuria as the most common genetic metabolic disorder is the result of disruption of the phenylalanine hy-
droxylase gene. This study was carried out to explore the phenylalanine hydroxylase gene mutation status of Iranian phenylketonuria 
patients.  
   Methods: Blood samples were collected from 30 patients, and hot spot areas of the phenylalanine hydroxylase gene, including exons 
6, 7, 8, 11, and 12 were studied through polymerase chain reaction and sequencing techniques.  
   Results: Eight different mutations, including 5 missense mutations, 1 splice mutation, 1 nonsense mutation, and 1 Silent/Splice mu-
tation were detected. These mutations were R243X, R261Q, R261X, P281L, R241C, V399V, E280K, and IVS11+1G>C. V399V and 
R241C were reported for the first time in Iranian population. Three polymorphisms including Q232Q, V245V and L385L and 3 novel 
intronic variants including IVS10-15A>C, IVS6+44T>G, and IVS6+36 T>G were also detected in this study.  
   Conclusion: The results of this study prove the heterogeneous status of phenylalanine hydroxylase gene mutations in the Iranian 
population, which can be useful in carrier testing and genetic counseling. 
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Introduction 
Phenylketonuria (PKU, OMIM 261600), a common 
metabolic genetic disorder, is identified by the lack of 
phenylalanine hydroxylase (PAH) enzyme (EC 1.14.16.1) 
activity (1). Phenylalanine (Phe) conversion to tyrosine by 
this enzyme is the main pathway for Phe metabolism, and 
this activity is dependent on tetrahydrobiopterin (BH4) 
presence as a cofactor (2). If this disease cannot be diag-
nosed in the first days after birth, it will contribute to the 
accumulation of phenylalanine in the patient’s body fluids 
with side effects such as failure in growth and brain dam-
ages (3). Newborn screening programs for PKU diagnosis 
are important postnatal requirement tests in many coun-
tries. The Guthrie test is the most applicable method for 
this purpose and has been used for more than 40 years (4). 
Based on blood Phe concentrations, PKU can be classified 
to classic PKU, mild PKU and mild hyperphenylala-
ninemia (HPA) (5).  
The human PAH gene (GenBank: AF404777) with 13 
exons is located on chromosome 12q22-q24.1, spanning 
about 90 kb, which encodes a polypeptide with 452 amino 
acids (6). The broad spectrum of mutations in PAH gene is 
the main etiology of this disease, and more than 800 dif-
ferent mutations are registered on the PAH mutation data-
base; most of them are missense. 
These mutations can make the enzyme structure and ac-
tivity dysregulated which leads to variable phenotypes 
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based on their severity to be observed (7). The presence of 
different disease-causing mutations in the biallelic PAH 
gene contributes to the compound heterozygosity status in 
most patients (8). The regional prevalence of PKU varies 
worldwide, and the highest frequency of this disease is 
observed among Caucasians with a rate of 1/10,000 per 
live births (5).  
Iran is a country with a high number of consanguine 
marriages showing a rate of 1.6 in 3,627 (9). Surveying 
PAH gene mutations is applicable in genetic counseling 
for prenatal diagnosis and presentation of an efficient die-
tary program for PKU patients (10). This study identifies 
the genetic mutation status of a group of Iranian PKU pa-
tients to expand the mutation database of different ethnic 
groups within this population proving beneficial for muta-
tion panel designs of laboratories and prevention of the 




A total of 30 unrelated PKU patients were chosen from 
the Institute of Endocrinology and Metabolism of Ali As-
ghar Hospital between August 2015 and July 2016. 
They were accepted into this study after their parents 
filled out the official consent form provided by the Ethical 
Committee of Iran University of Medical Sciences. The 
classification of patients into classic and mild PKU was 
based on their blood phenylalanine concentrations. Most 
of them were identified during neonatal screening pro-
grams by a Guthrie test. These patients, between 8 months 
to 18 years old, were from different ethnic groups in Iran. 
DNA Extraction: A 5 ml blood sample was collected 
from each patient. The genomic DNA was extracted from 
leukocytes isolated from EDTA anticoagulated blood, 
using a DNA purification Genet Bio kit (South Korea). 
DNA Purity and quality were assessed by NanoDrop 
Spectrophotometer (Thermo Scientific™, USA) and 1% 
agarose gel respectively.  
 PCR: The choice of PAH gene exons including 6, 7, 8, 
11, and 12 was based on their high mutation rates in pre-
vious literature (6, 11). These 5 exons and their adjacent 
intronic regions were separately amplified by PCR on the 
T100™ Thermal Cycler system (Bio-Rad Laboratories, 
Hercules, CA, USA) (Fig. 1).  
The primers were chosen from previous studies (Table 
1) (12). PCR reactions were carried out in a total volume 
of 25 μl containing 2.4 µL of 2× reaction buffer, 2 µL of 
genomic DNA templates, 0.1 µL of Taq DNA polymerase 
(5 U/µL), 0.7 µL of each primer, 1.5 µL MgCl2 (50 mM) 
and 0.5 µM of dNTP (10 mM). The cycling program of 
 
Fig. 1. The analysis of PCR amplification of exons 6, 7, 8, 11 and 12 on 1% 
agarose gel; M- Marker; A- exon 6 (283 bp); B- exon 7 (256); C- exon 8 
(194); D- exon 11 (260); E- exon 12 (232). 
 
Table 1. The list of primer sequences and expected PCR product sizes 
Exons Primers Annealing temperature (°C) PCR product length 
6 F: TGCCCTGCTTGAGACACCTA 
R: TCCTCCCCCAACTTTCTGC 
60 283 
7 F: CCTCTGACTCAGTGGTGA 
R: CTTGCAGCAGGAAAAG 
59 256 
8 F: CTGAGTCTGGCTTGGCTTAA 
R: CTCATTTGAGAAATTCAGGT 
58 194 
11 F: TGCAGCAGGGAATACTGA 
R: AGATGAGTGGCACCAGT 
60 260 
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PCR was 94 ˚C denaturation for 3 min, followed by 35 
cycles of denaturation at 94 ºC for 45 s, annealing at 59 ˚C 
for 30 s, extension at 72 ºC for 45 s, and a final extension 
step at 72 ºC for 3 min. The 1% agarose gel was used for 
electrophoresis of PCR amplicons. 
 DNA Sequencing: The PCR products were purified 
and sequenced using PCR forward and reverse primers by 
the Applied Biosystems 3730 DNA Analyzer (Macrogen, 
Seoul, Korea) using the classic Sanger’s method.  
 
Data Analysis 
Mutations and polymorphisms were detected by soft-
ware and programs including ChromasPro (Technelysium, 
South Brisbane Australia), Sequence Scanner (Applied 
Biosystems, US), Mutation Surveyor (SoftGenetics, Penn-
sylvania, USA), and nucleotide blast program of NCBI. 
These ones were then identified by comparison with the 
reference sequence in GenBank (www.ncbi.nlm.nih. 
gov/genbank), available genetic data in PAH database 
(http://www.pahdb.mcgill.ca), and SNP database of NCBI 
(www.ncbi.nlm.nih.gov/snp). 
 The clinical significance of mutations was character-
ized by using ClinVar (www.ncbi.nlm.nih.gov/clinvar/) 
database. The analysis of new variants was carried out by 
Mutation Taster (http://www.mutationtaster.org/) and 
CADD (http://cadd.gs.washington.edu/) online bioinfor-
matics tools.  
 
Results 
The patients (15 females and 15 males), aged between 8 
months to 18 years old, were examined. They were from 
different parts of Iran, and their ethnicity was also diverse 
such as Kurdish, Azeri, and Persian. The rate of consan-
guine marriage was 53%, and most of the parents were 
third cousins. A total of 8 different mutations consisting of 
5 missense mutations, 1 splice mutation, 1 nonsense muta-
tion, and 1 Silent/Splice mutation were characterized in 14 
alleles. The rate of mutation detection was about 23.3%. 
Three polymorphisms and four intronic novel variations 
were characterized as well.  
The mutations, including c.782G>A, c.838 G>A, 
c.842C>T, c.721C>T, c.727C>T, c.1197A>T, c.781C>T 
and IVS11+1G>C, the polymorphisms including 
c.696A>G, c.735G>A and c.1155G>C and the novel in-
tronic variants including IVS6+44T>G, IVS6+36T>G, 
and IVS10-15A>C were identified (Table 2). The survey 
of pathogenic variations in ClinVar database also proved 
their pathogenic effect (Table 3). The genotype and phe-
notype information of patients were demonstrated in Table 
4. Some associations were also observed in this study and 
Table 2. Relative frequency of variations and prediction of their effect 









Exon7 c.782G>A p .R261Q 4 6.66 6.198 1 Disease causing 
Exon7 c.781C>T p .R261X 2 3.33 2.582 1 Disease causing 
Exon7 c.838G>A p .E280K 1 1.66 6.203 1 Disease causing 
Exon7 c.842C>T p .P281L 2 3.33 6.203 1 Disease causing 
Exon7 c.721C>T p .R241C 1 1.66 4.439 1 Disease causing 
Exon7 c.727C>T p .R243X 2 3.33 2.751 1 Disease causing 
Exon 11 c.1197A>T p .V399V 1 1.66 0.423 1 Disease causing 
Intron11 c.1199+1G>C IVS11+1G>C 1 1.66 6.012 1 Disease causing 
Exon 6 c.696A>G p .Q232Q 7 11.6 -3.252 0.005 polymorphism 
Exon7 c.735G>A p .V245V 7 11.6 0.873 1 Polymorphism 
Exon11 c.1155G>C p .L385L 2 3.3 -0.213 0.749 Polymorphism 
Intron6 c.706+36T>G IVS6+36 T>G 1 1.6 -0.172 0 Polymorphism 
Intron 6 c.706+44T>G IVS6+44T>G 1 1.6 -0.986 0.004 Polymorphism 
Intron 10 c.1066-15A>C IVS10-15A>C 3 5 0.479 0 Polymorphism 
 
Table 3. Clinical significance of mutations 
Mutation rs Number Clinical significance 
R261Q rs62508698 Pathogenic 
R261X rs5030850 Pathogenic 
E280K rs62508698 Pathogenic 
P281L rs5030851 Pathogenic 
R241C rs76687508 Pathogenic 
R243X rs5030846 Pathogenic 
V399V rs199475584 Pathogenic 
IVS11+1G>C rs62509015 Likely pathogenic 
 
Table 4. Genotypes and characteristics of 12 patients 
Patients 
ID 
Location Genotypes Classification HPA Type Ethnicity Pre-treatment Phe levels 
(mg/dl) 
5 Exon 11 L385L/U Heterozygote Classic Azeri  21.5 
6 Exon 7 V245V/U 
E280K/U 
Heterozygote Mild HPA Persian 18.4 
7 Exon 7 R261Q/ U Heterozygote Mild HPA  
Persian 
 
16.7 7 Exon 6 Q232Q/ U Heterozygote 
8 Exon 7 V245V/U Heterozygote Mild HPA Kurdish 14 
9 Exon 6 Q232Q/ Q232Q Homozygote Mild HPA Persian 15 
11 Exon 7 P281L/ P281L Homozygote Classic Persian 25 
12 Exon 7 R241C/U 
V245V/U 
Heterozygote Classic Azeri  21.1 
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one of them, including R243X mutation and V245V 
polymorphism was shown in Fig. 2. The mean quality 
value of surrounding nucleotides of these variants was 
higher than 50 which proved their accuracy. The PHRED 
score of these novel variants showed their non-pathogenic 
effect (Table 5). 
 
Discussion 
Phenylketonuria, a metabolic autosomal recessive ge-
netic disorder, is the consequence of PAH gene deficien-
cy. The hallmark of this disease is  high blood serum Phe 
levels with a low-Phe diet as the cornerstone of its treat-
ment (13). Mutations in the BH4 gene also resulted in 
hyperphenylalaninemia, and identification of related mu-
tations to PAH enzyme can be applicable in the prescrip-
tion of BH4 based therapies (14). Patients were diagnosed 
based on their high blood Phe and in order to confirm mild 
HPA cases for having PAH mutations, analysis of DHPR 
and biopterin-neopterin was carried out. 
In this study, molecular characterization of exons 6, 7, 
8, 11, and 12 in 30 Iranian patients showed a 23.3% muta-
tion detection rate. Ten percent of patients were homozy-
gote for mutations. Three polymorphisms including 
Q232Q (11.6%) in exon 6, V245V (11.6%) in exon 7 
(11.6%) and L385L (3.33%) in exon 11 were also identi-
fied. The R261Q mutation (6.66%) in exon 7 was ob-
served in two patients in heterozygote form and one pa-
tient in homozygote form which affects a CpG mutation 
hot spot in nucleotide 782 of PAH gene. The explanation 
of this mutation mechanism is by the 5-methylcytosine 
deamination at a CpG dinucleotide site which contributes 
to the change of amino acid Arg to Glutamine. This one is 
the second most common mutation in Turkey, which is 
also common in European nations like France (17%), and 
Italy (16%) (15, 16). The presence of Mediterranean mu-
tations in our patients may prove the historical connection 
between Iranian and Mediterranean populations. 
The R261X mutation which is the result of C to T con-
version at codon 781 of PAH gene is placed in its catalytic 
domain (residues 118-427) (17). P281L (3.33%), a mis-
sense mutation in homozygote form, is the result of C to T 
substitution at codon 842 of PAH gene. This nucleotide 
position is in the region of cofactor binding domain. 
Table 4. Cntd 
14 Exon 7 R261Q/U Heterozygote Classic Persian 24 
15 Exon 6 Q232Q/ Q232Q Homozygote Classic Persian 26 
R261X/R261X Homozygote 
16 Exon 6 Q232Q/ Q232Q Homozygote Classic Azeri  25 
18 Exon 11 V399V/U Heterozygote Classic Persian 28.8 
Exon 7 V245V Homozygote 
19 Exon 7 R243X/ R243X 
V245V/ V245V 
Homozygote Classic Azeri 22.9 




Heterozygote Classic Persian 23.4 








Fig. 2. Mutation analysis of R243X (c.727C>T) nonsense mutation and V245V (c.735G>A) polymorphism in exon 7 of PAH gene 
 
Table 5. The PHRED score of new variants 
PHRED Score Variant 
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P281L has been identified in classic PKU patients fre-
quently. Previous studies in Iran have also reported this 
mutation (11).  
R243X (3.3%) as a nonsense mutation is located in exon 
7 of PAH gene, which was observed along with V245V as 
a polymorphism in one classic patient. These ones were in 
homozygote form and had located in 21th and 29th base of 
exon 7 respectively. Two associations in heterozygote 
patients, including R241C (1.66%) with V245V and 
E280K (1.66%) with V245V were also reported, which 
have not been reported previously in PAHdb. R241C is 
classified as the BH4-responsiveness mutation reported 
for the first time in the Iranian population.  
The splice mutation IVS11+1G>C/U (1.66%) and 
L385L polymorphism were observed in intron 11 and ex-
on 11 of one classic PKU patient. The V399V (1.66%) 
mutation had been identified in the Chinese population for 
the first time (17). The c.1197 nucleotide is located at the 
3'-end of exon 11 at position -3′ of the exon-intron bound-
ary, and transition of A to T in this position cause exon 
skipping as a post-transcriptional event which can result in 
deficient PAH mRNA (18). This heterozygote one was 
observed in a classic patient and was the first report of this 
mutation in Iran.  
 
Conclusion 
The results of our study proved the existence of hetero-
geneous mutations in different ethnic groups in Iran. The 
highest rate of mutations was observed in exon 7, and no 
mutation was observed in exon 8. It should be considered 
that our results showed two mutations which had not been 
reported previously in Iran.  
So by monitoring diverse ethnic groups in Iran, other 
novel mutations will be easier to find and identify. This 
data can be useful for genetic counseling and carrier de-
tection tests and as a base to start further research from.  
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